AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23298304 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal, submucosal injection of 4 x 1 mL of dextranomer in hyaluronic acid
Number of subjects: 126
Study 23298304 — intervention group
Group type: COMPARATOR
Intervention: Sphincter training with biofeedback
Number of subjects: 126
Study 23298304 — intervention group
Group type: COMPARATOR
Intervention: Comparison of St Mark's scores between the groups
Number of subjects: 126
Study 22182346 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 34
Study 22182346 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 34
Study 19248862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/low-glycemic load diet
Number of subjects: 8
Study 19248862 — intervention group
Group type: COMPARATOR
Intervention: Standard American diet
Number of subjects: 8
Study 16705845 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinger moxibustion
Number of subjects: 78
Study 16705845 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 78
Study 15134793 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen room
Number of subjects: 15
Study 15134793 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational skills training
Number of subjects: 15
Study 15134793 — intervention group
Group type: COMPARATOR
Intervention: Activities of Daily Living (ADL) skills training
Number of subjects: 15
Study 11734939 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Look CAD (CADx Medical Systems, Quebec, Canada)
Number of subjects: 150
Study 9215249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg/day)
Number of subjects: 15
Study 9215249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7897254 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 24
Study 2888648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam
Number of subjects: 0
Study 2888648 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum and hyoscine
Number of subjects: 0
Study 31339474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 13483
Study 31339474 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 13483
Study 31339474 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD (eGFR < 60 mL/min/1.73 m2)
Number of subjects: 13483
Study 28775001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal theophylline
Number of subjects: 161
Study 28775001 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 26036454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (8-week randomized controlled trial)
Number of subjects: 187
Study 26036454 — intervention group
Group type: COMPARATOR
Intervention: Remitted recurrent MDD patients
Number of subjects: 187
Study 26036454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 187
Study 23770517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training (3 sessions)
Number of subjects: 5
Study 22104038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine (25-day course of tablets)
Number of subjects: 1310
Study 22104038 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) (usual care: eight weeks of NRT patch and/or gum or lozenge)
Number of subjects: 1310
Study 19665037 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Across the Curriculum (PAAC) intervention
Number of subjects: 24
Study 19665037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 17102775 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus+sirolimus
Number of subjects: 54
Study 17102775 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus+mycophenolate mofetil (MMF)
Number of subjects: 54
Study 17102775 — intervention group
Group type: COMPARATOR
Intervention: sirolimus+MMF+daclizumab
Number of subjects: 54
Study 15650072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliance (FOA)
Number of subjects: 27
Study 14551293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy (fluorouracil‐leucovorin)
Number of subjects: 105
Study 14551293 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment consisting of systemic chemotherapy (fluorouracil‐leucovorin) with or without palliative surgery
Number of subjects: 105
Study 14551293 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC group with 0 to 5 regions of the abdominal cavity involved by tumor
Number of subjects: 105
Study 14551293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction was macroscopically complete (R-1)
Number of subjects: 105
Study 10085543 — intervention group
Group type: EXPERIMENTAL
Intervention: High event-cue frequency
Number of subjects: 0
Study 10085543 — intervention group
Group type: COMPARATOR
Intervention: General knowledge test
Number of subjects: 0
Study 10085543 — intervention group
Group type: COMPARATOR
Intervention: Prose-reading task
Number of subjects: 0
Study 10085543 — intervention group
Group type: EXPERIMENTAL
Intervention: First and final set of event-cues under high event-cue frequency conditions
Number of subjects: 0
Study 7601919 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival application of 2% minocycline ointment administered at baseline, week 2, and months 1, 3, 6, and 9.
Number of subjects: 20
Study 7601919 — intervention group
Group type: COMPARATOR
Intervention: Systemic administration of minocycline following scaling/root planing for 10 days.
Number of subjects: 20
Study 7601919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subgingival and systemic administration groups.
Number of subjects: 20
Study 2224377 — intervention group
Group type: EXPERIMENTAL
Intervention: Early operation (surgery completed by follow-up)
Number of subjects: 40
Study 2224377 — intervention group
Group type: COMPARATOR
Intervention: Control group (awaiting surgery)
Number of subjects: 40
Study 352236 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopa
Number of subjects: 20
Study 352236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 20
Study 352236 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 20
Study 30972456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/day)
Number of subjects: 14
Study 30972456 — intervention group
Group type: COMPARATOR
Intervention: Control (no rabeprazole)
Number of subjects: 14
Study 30972456 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 14
Study 27855293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered distal tip guidewire (0.010in. or less)
Number of subjects: 260
Study 27855293 — intervention group
Group type: COMPARATOR
Intervention: Regular distal tip guidewire (0.014in. size)
Number of subjects: 260
Study 26523444 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-A (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 2400 mg/m2, nab-paclitaxel 150 mg/m2 every 2 weeks)
Number of subjects: 35
Study 26523444 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-A (oxaliplatin 65 mg/m2 if grade 2 neuropathy developed)
Number of subjects: 35
Study 26523444 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-A (with cumulative neurotoxicity assessment)
Number of subjects: 35
Study 25091854 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 36
Study 25091854 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT 30
Number of subjects: 36
Study 25091854 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT 15
Number of subjects: 36
Study 25091854 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ET, SIT 30, SIT 15)
Number of subjects: 36
Study 21857520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 84 mg (group A)
Number of subjects: 80
Study 21857520 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 7 mg along with fentanyl 10 μg (group B+F)
Number of subjects: 80
Study 19150019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (dietary modification, physical activity, educational sessions)
Number of subjects: 0
Study 19150019 — intervention group
Group type: COMPARATOR
Intervention: Normal recommendations (control group)
Number of subjects: 0
Study 17242084 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 20
Study 17242084 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive sham acupuncture
Number of subjects: 20
Study 15069044 — intervention group
Group type: EXPERIMENTAL
Intervention: PEARLS intervention (n = 72)
Number of subjects: 138
Study 15069044 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 66)
Number of subjects: 138
Study 12230024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mao-to (8 patients)
Number of subjects: 28
Study 12230024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai-seiryu-to (4 patients)
Number of subjects: 28
Study 12230024 — intervention group
Group type: COMPARATOR
Intervention: IFN-beta alone (16 patients in group C)
Number of subjects: 28
Study 9862250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (lipophilic ACEI)
Number of subjects: 0
Study 9862250 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (hydrophilic ACEI)
Number of subjects: 0
Study 9862250 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (vasoconstrictor)
Number of subjects: 0
Study 9862250 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F2alpha (PGF2alpha)
Number of subjects: 0
Study 7646751 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month intensive training program in psychosocial medicine
Number of subjects: 26
Study 7646751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive training)
Number of subjects: 26
Study 29961045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofu-Net (stepped, collaborative and coordinated health care network)
Number of subjects: 218
Study 29961045 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 218
Study 26815944 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 325
Study 26815944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 26815944 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in patients with a history of uveitis
Number of subjects: 325
Study 26815944 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with a history of uveitis
Number of subjects: 325
Study 26815944 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in AS patients
Number of subjects: 325
Study 26815944 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) in nr-axial SpA patients
Number of subjects: 325
Study 24996511 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive patient information material
Number of subjects: 0
Study 24996511 — intervention group
Group type: COMPARATOR
Intervention: Standard translated patient information material
Number of subjects: 0
Study 23880099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (10 mg kg(‐1) followed by 1 mg kg(‐1) h(‐1) infusion and 1 mg kg(‐1) into the CPB)
Number of subjects: 61
Study 23880099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (30 mg kg(‐1) followed by 16 mg kg(‐1) h(‐1) infusion and 2 mg kg(‐1) into the CPB)
Number of subjects: 61
Study 20626383 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 107
Study 20626383 — intervention group
Group type: COMPARATOR
Intervention: PEG + Bis
Number of subjects: 107
Study 18853230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-enriched pasta
Number of subjects: 22
Study 18853230 — intervention group
Group type: COMPARATOR
Intervention: Control pasta
Number of subjects: 22
Study 16573869 — intervention group
Group type: EXPERIMENTAL
Intervention: Guards
Number of subjects: 0
Study 16573869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisoners
Number of subjects: 0
Study 16573869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrannical regime
Number of subjects: 0
Study 14687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 357
Study 14687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR)
Number of subjects: 357
Study 14687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (COMBO)
Number of subjects: 357
Study 14687273 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbers Needed to Treat (NNT)
Number of subjects: 357
Study 10934090 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (80 mg twice daily)
Number of subjects: 368
Study 10934090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 8755677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received smoking prevention program)
Number of subjects: 206
Study 8755677 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (did not receive smoking prevention program)
Number of subjects: 206
Study 1557595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18
Study 1557595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 5 mg/24 hours
Number of subjects: 16
Study 3926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 10 mg/24 hours
Number of subjects: 16
Study 3926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 20 mg/24 hours
Number of subjects: 16
Study 3926612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches delivering 30 mg/24 hours
Number of subjects: 16
Study 31988233 — intervention group
Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib) 400 mg daily for 21 days
Number of subjects: 47
Study 31988233 — intervention group
Group type: EXPERIMENTAL
Intervention: LEE011 (ribociclib)
Number of subjects: 47
Study 30485685 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium administered 30 minutes before surgery.
Number of subjects: 88
Study 30485685 — intervention group
Group type: COMPARATOR
Intervention: Saline administered 30 minutes before surgery (Control group).
Number of subjects: 88
Study 26255814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound exercise (3 times per week for 20-30 minutes over 9 weeks at moderate intensity of 40-60% of heart rate maximum)
Number of subjects: 90
Study 26255814 — intervention group
Group type: COMPARATOR
Intervention: Control group (watched videos and read health magazines)
Number of subjects: 90
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with additional support delivered by telephone and internet
Number of subjects: 24152
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline forms returned by patients
Number of subjects: 24152
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-related reasons for declining participation
Number of subjects: 24152
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Health need-related reasons for declining participation
Number of subjects: 24152
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Life circumstances-related reasons for declining participation
Number of subjects: 24152
Study 26044763 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-related reasons for declining participation
Number of subjects: 24152
Study 23589163 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) (100 μg/day) + ibandronate (150 mg/month)
Number of subjects: 43
Study 21037431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion
Number of subjects: 164
Study 21037431 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage
Number of subjects: 164
Study 18670706 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2mg/kg/day of ferrous sulfate + folic acid (50microg)
Number of subjects: 196
Study 18670706 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4mg/kg/day of ferrous sulfate + folic acid (50microg/day)
Number of subjects: 196
Study 18670706 — intervention group
Group type: COMPARATOR
Intervention: 4.2mg/kg/day of ferrous sulfate + folic acid placebo
Number of subjects: 196
Study 18670706 — intervention group
Group type: COMPARATOR
Intervention: 1.4mg/kg/day of ferrous sulfate + folic acid placebo
Number of subjects: 196
Study 15837454 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention (targeted communication about fall and fracture prevention and osteoporosis diagnosis and treatment delivered through mailings)
Number of subjects: 31715
Study 15837454 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician intervention (one‐on‐one academic detailing encounters covering fall and fracture prevention and osteoporosis)
Number of subjects: 31715
Study 15837454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient and physician interventions
Number of subjects: 31715
Study 15837454 — intervention group
Group type: COMPARATOR
Intervention: No patient and no physician intervention
Number of subjects: 31715
Study 15837454 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention
Number of subjects: 31715
Study 12544411 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (highly active antiretroviral therapy)
Number of subjects: 19
Study 10486394 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg/day
Number of subjects: 100
Study 10486394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate 1500 mg/day
Number of subjects: 100
Study 10486394 — intervention group
Group type: COMPARATOR
Intervention: Both Phenytoin and Sodium Valproate
Number of subjects: 100
Study 8897531 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide and eugenol (ZOE)
Number of subjects: 38
Study 8897531 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 38
Study 1797358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg metaraminol
Number of subjects: 80
Study 1797358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg metaraminol
Number of subjects: 80
Study 1797358 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg metaraminol
Number of subjects: 80
Study 1797358 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 80
Study 1797358 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol (all doses)
Number of subjects: 80
Study 6338760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol continued until operation (N = 10)
Number of subjects: 20
Study 6338760 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol discontinued before operation (N = 10)
Number of subjects: 20
Study 30057090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lymphoma survivorship clinic intervention
Number of subjects: 10
Study 29231297 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy applied to acupoints in the neck and lumbus (Fengchi (GB 20), Tianzhu (BL 10), Neck-Bailao (EX-HN 15), Wangu (GB 12), Tianyou (TE 16), Dachangshu (BL 25), Qihaishu (BL 24), Jiaji (EX-B 2) of L5). Treatment given once every two days, three times a week.
Number of subjects: 81
Study 29231297 — intervention group
Group type: COMPARATOR
Intervention: Warm needling therapy applied only to acupoints in the neck (same as group A). Treatment given once every two days, three times a week.
Number of subjects: 81
Study 24973931 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed running suture
Number of subjects: 411
Study 24973931 — intervention group
Group type: COMPARATOR
Intervention: Knotted interrupted suture (Control)
Number of subjects: 411
Study 23770206 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous choice learning condition with food provided
Number of subjects: 3
Study 23770206 — intervention group
Group type: COMPARATOR
Intervention: Controlled choice learning condition with food provided
Number of subjects: 3
Study 23770206 — intervention group
Group type: COMPARATOR
Intervention: Controlled choice learning condition without food provided
Number of subjects: 3
Study 19731015 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >= 30 kg/m2)
Number of subjects: 2887
Study 19731015 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients (BMI < 30 kg/m2)
Number of subjects: 2887
Study 18781850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day, n = 420)
Number of subjects: 724
Study 18781850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 304)
Number of subjects: 724
Study 16373648 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg of folate, 25 mg of B6, and 400 microg of B12)
Number of subjects: 299
Study 16373648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 14760042 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes shared care
Number of subjects: 183
Study 14760042 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 183
Study 10958125 — intervention group
Group type: EXPERIMENTAL
Intervention: Community educational intervention
Number of subjects: 3013
Study 10958125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3013
Study 9048404 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily for 1 month (30 +/‐ 4 days)
Number of subjects: 262
Study 9048404 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month (30 +/‐ 4 days)
Number of subjects: 262
Study 8504499 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg aspirin daily
Number of subjects: 27
Study 8504499 — intervention group
Group type: COMPARATOR
Intervention: 50 mg aspirin daily
Number of subjects: 27
Study 3315266 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration at 2000 hr
Number of subjects: 30
Study 3315266 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration at 2200 hr
Number of subjects: 30
Study 3315266 — intervention group
Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 30